BioCorRx Reports Dec 29 Officer/Director Changes, Comp Arrangements
Ticker: BICX · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1443863
| Field | Detail |
|---|---|
| Company | Biocorrx Inc. (BICX) |
| Form Type | 8-K |
| Filed Date | Jan 5, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $200,000, $16,666.66 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, governance
TL;DR
**BioCorRx filed an 8-K about executive changes and pay on Dec 29, watch for details.**
AI Summary
BioCorRx Inc. filed an 8-K on January 5, 2024, reporting an event that occurred on December 29, 2023, related to the departure or election of directors/officers and their compensatory arrangements. This filing indicates potential changes in leadership or executive compensation, which could impact the company's strategic direction and financial health. Investors should monitor subsequent filings for details on these changes, as they could signal shifts in company performance or governance, affecting stock valuation.
Why It Matters
Changes in executive leadership or compensation can significantly influence a company's future strategy, operational efficiency, and financial stability, directly impacting shareholder value.
Risk Assessment
Risk Level: medium — The filing indicates changes in leadership or compensation, which can introduce uncertainty regarding future company direction and performance, warranting a medium risk assessment.
Analyst Insight
A smart investor would await further detailed disclosures regarding the specific personnel changes and compensatory arrangements to assess their potential impact on BioCorRx Inc.'s future operations and financial outlook before making investment decisions.
Key Players & Entities
- BioCorRx Inc. (company) — the registrant filing the 8-K
- December 29, 2023 (date) — date of the earliest event reported
- January 5, 2024 (date) — date the 8-K was filed
- Nevada (company) — state of incorporation for BioCorRx Inc.
- 000-54208 (company) — Commission File Number for BioCorRx Inc.
FAQ
What specific event did BioCorRx Inc. report in this 8-K filing?
BioCorRx Inc. reported an event concerning the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as per Item Information.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on December 29, 2023.
What is the filing date of this 8-K?
The filing date of this 8-K is January 5, 2024.
What is BioCorRx Inc.'s state of incorporation?
BioCorRx Inc.'s state of incorporation is Nevada.
What is the business address of BioCorRx Inc.?
The business address of BioCorRx Inc. is 2390 East Orangewood Avenue, Suite 500, Anaheim, CA 92806.
Filing Stats: 951 words · 4 min read · ~3 pages · Grade level 10.6 · Accepted 2024-01-05 16:30:28
Key Financial Figures
- $200,000 — . Lucido an annual compensation rate of $200,000 to be paid in equity in monthly install
- $16,666.66 — d on the number of shares equivalent to $16,666.66 as determined by the average closing pr
Filing Documents
- bicx_8k.htm (8-K) — 29KB
- bicx_ex101.htm (EX-10.1) — 41KB
- 0001477932-24-000065.txt ( ) — 195KB
- bicx-20231229.xsd (EX-101.SCH) — 6KB
- bicx-20231229_lab.xml (EX-101.LAB) — 13KB
- bicx-20231229_cal.xml (EX-101.CAL) — 1KB
- bicx-20231229_pre.xml (EX-101.PRE) — 8KB
- bicx-20231229_def.xml (EX-101.DEF) — 2KB
- bicx_8k_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 10.1 Executive Service Agreement with Louis Lucido, dated January 5, 2024 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. BioCorRx Inc. Date: January 5, 2024 By: /s/ Lourdes Felix Lourdes Felix Chief Executive Officer 4